조현병 및 조현정동장애 입원환자에서 혈청 염증표지자와 정신병적 증상과의 관련성
Relationship between Serum Inflammatory Marker and Psychotic Symptoms in Inpatients with Schizophrenia or Schizoaffective Disorder
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Objectives : Despite the growing research interest in the role of immunological markers in schizophrenia, a few studies, with conflicting results, have focused on the association between high sensitivity C-reactive protein (hs-CRP) levels and clinical characteristics in schizophrenia. The aim of the present study was to examine the association of serum hs-CRP with psychopathology in schizophrenia. Methods : Fifty-five inpatients with schizophrenia or schizoaffective disorder were enrolled. Serum levels of hs-CRP were measured, and each patient was assessed with the Korean version of the Positive and Negative Syndrome Scale (PANSS). Results : In correlation analysis of hs-CRP with PANSS subscales, positive subscale score has significant positive correlation (r = 0.271, p = 0.046). In independent t-test analysis, subjects with hs-CRP ＞ 0.3 mg/dL (elevated CRP group, n = 43) had significantly higher PANSS positive subscale score (t = -3.273, df = 24.107, p = 0.003) than those with hs-CRP ≤ 0.3 mg/dL (normal CRP group, n = 12). Conclusions : Elevated serum levels of high sensitivity C-reactive protein in schizophrenia are associated with the severity of psychotic symptoms.
Abstract
Objectives : Despite the growing research interest in the role of immunological markers in schizophrenia, a few studies, with conflicting results, have focused on the association between high sensitivity C-reactive protein (hs-CRP) levels and clinical characteristics in schizophrenia. The aim of the present study was to examine the association of serum hs-CRP with psychopathology in schizophrenia. Methods : Fifty-five inpatients with schizophrenia or schizoaffective disorder were enrolled. Serum levels of hs-CRP were measured, and each patient was assessed with the Korean version of the Positive and Negative Syndrome Scale (PANSS). Results : In correlation analysis of hs-CRP with PANSS subscales, positive subscale score has significant positive correlation (r = 0.271, p = 0.046). In independent t-test analysis, subjects with hs-CRP ＞ 0.3 mg/dL (elevated CRP group, n = 43) had significantly higher PANSS positive subscale score (t = -3.273, df = 24.107, p = 0.003) than those with hs-CRP ≤ 0.3 mg/dL (normal CRP group, n = 12). Conclusions : Elevated serum levels of high sensitivity C-reactive protein in schizophrenia are associated with the severity of psychotic symptoms.
참고문헌 (38)
- Yolken RH, "Viruses, schizophrenia, and bipolar disorder", Clin Microbiol Rev, 8, pp.131~145 (1995)
- Maes M, "Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor", Schizophr Res, 54, pp.281~291 (2002)
- Müller N, "The immune system and schizophrenia. An integrative view", Ann N Y Acad Sci, 917, pp.456~467 (2000)
- Rapaport MH, "Serum-soluble interleukin-2 receptors in neuroleptic-naive schizophrenic subjects and in medicated schizophrenic subjects with and without tardive dyskinesia", Acta Psychiatr Scand, 90, pp.311~315 (1994)
- Sirota P, "Effect of neuroleptic administration on serum levels of soluble IL-2 receptor-alpha and IL-1 receptor antagonist in schizophrenic patients", Psychiatry Res, 134, pp.151~159 (2005)
- Clinical Psychiatry. 10th ed, "Kaplan & Sadock’s Synopsis of Psychiatry: Behavioral Sciences", pp.2007, Sadock BJ
- Lin A, "The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6", Schizophr Res, 32, pp.9~15 (1998)
- Naudin J, "A differential role for interleukin-6 and tumor necrosis factor-alpha in schizophrenia?", Schizophr Res, 26, pp.227~233 (1997)
- Licinio J, "Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients", Am J Psychiatry, 150, pp.1408~1410 (1993)
- el-Mallakh RS, "Interleukin-1 alpha and interleukin-2 in cerebrospinal fluid of schizophrenic subjects", Prog Neuropsychopharmacol Biol Psychiatry, 17, pp.383~391 (1993)
- Rapaport MH, "CSF IL-1 and IL-2 in medicated schizophrenic patients and normal volunteers", Schizophr Res, 25, pp.123~129 (1997)
- McAllister CG, "Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status", Am J Psychiatry, 152, pp.1291~1297 (1995)
- Müller N, "Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia", Am J Psychiatry, 159, pp.1029~1034 (2002)
- Rapaport MH, "Celecoxib augmentation of continuously ill patients with schizophrenia", Biol Psychiatry, 57, pp.1594~1596 (2005)
- Zhang XY, "Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia", J Clin Psychiatry, 65, pp.940~947 (2004)
- Zakharyan R, "Genetic variants of the inflammatory C-reactive protein and schizophrenia in Armenian population: a pilot study", Int J Immunogenet, 37, pp.407~410 (2010)
- Meyer JM, "Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study", Biol Psychiatry, 66, pp.1013~1022 (2009)
- Lowe GD, "Circulating inflammatory markers and risks of cardiovascular and non-cardiovascular disease", J Thromb Haemost, 3, pp.1618~1627 (2005)
- Bassuk SS, "High-sensitivity C-reactive protein: clinical importance", Curr Probl Cardiol, 29, pp.439~493 (2004)
- Pfützner A, "High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus", Diabetes Technol Ther, 8, pp.28~36 (2006)
- Akanji AO, "Association of blood levels of C-reactive protein with clinical phenotypes in Arab schizophrenic patients", Psychiatry Res, 169, pp.56~61 (2009)
- Fawzi MH, "C-reactive protein serum level in drug-free male Egyptian patients with schizophrenia", Psychiatry Res, 190, pp.91~97 (2011)
- Dickerson F, "C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia", Schizophr Res, 93, pp.261~265 (2007)
- Schattner A, "No evidence for autoimmunity in schizophrenia", J Autoimmun, 9, pp.661~666 (1996)
- Coe CL, "Population differences in proinflammatory biology: Japanese have healthier profiles than Americans", Brain Behav Immun, 25, pp.494~502 (2011)
- Fan X, "Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia", Psychiatry Res, 149, pp.267~271 (2007)
- 이중서, "한국판 양성 및 음성증후군 척도(Positive and Negative Syndrome Scale)의 신뢰도와 타당도", 신경정신의학, 40(6), pp.1090~1105 (2001), 대한신경정신의학회
- Mazzarello V, "Lymphocytes in schizophrenic patients under therapy: serological, morphological and cell subset findings", Ital J Anat Embryol, 109, pp.177~188 (2004)
- Maes M, "Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics", Eur Neuropsychopharmacol, 10, pp.119~124 (2000)
- Bachneff SA, "Regional cerebral blood flow in schizophrenia and the local circuit neurons hypothesis", Schizophr Bull, 22, pp.163~182 (1996)
- Shinba T, "Near-infrared spectroscopy analysis of frontal lobe dysfunction in schizophrenia", Biol Psychiatry, 55, pp.154~164 (2004)
- Hanson DR, "Theories of schizophrenia: a genetic-inflammatory-vascular synthesis", BMC Med Genet, 6, pp.7~ (2005)
- Lee SG, "Correlations between serum C-Reactive Protein levels and symptoms of bipolar mania and schizophrenia", J Soc Korean Women Psychiatr, 9, pp.45~52 (2011)
- Naudin J, "Elevated circulating levels of IL-6 in schizophrenia", Schizophr Res, 20, pp.269~273 (1996)
- Zhang XY, "Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology", Schizophr Res, 57, pp.247~258 (2002)
- Akiyama K, "Serum levels of soluble IL-2 receptor alpha, IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration", Schizophr Res, 37, pp.97~106 (1999)
- Maes M, "Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers", J Psychiatr Res, 29, pp.141~152 (1995)
- Yolken RH, "Viruses, schizophrenia, and bipolar disorder", Clin Microbiol Rev, 8, pp.131~145 (1995)